Royalty Pharma plc growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +7.8%
EBITDA: -15.7%
EBIT: -12.8%
EPS: -0.2%
Free cash flow: -1.7%
Operating cash flow: -1.7%

Forward estimates

Revenue: +46.1%
EBITDA: +25.5%
EPS: +121.1%

Three-year CAGR

Revenue: +2.1%
EBITDA: +56.9%
EBIT: +71.9%
Net income: +162.1%
EPS: +185.6%
Free cash flow: +5.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.